ZYME
Zymeworks·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ZYME Profile
Zymeworks Inc.
A company that develops multifunctional biotherapeutics for the treatment of cancer
108 Patriot Drive — Suite A, Middletown, Delaware 19709
--
Zymeworks Inc., was incorporated under the laws of the State of Delaware in June 2022. Zymeworks is a clinical-stage biopharmaceutical company that develops a diverse pipeline of novel multifunctional biotherapeutic drugs to improve the standard of care for difficult-to-treat diseases. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab, is a novel Azymetric HER2 targeting bispecific antibody currently being evaluated in multiple Phase 1, 2 and pivotal clinical trials worldwide as a targeted therapy option for patients with solid tumors expressing HER 2. Zymeworks' second clinical candidate, Zanidatamab Zovodotin (ZW49), is a novel bispecific HER2 targeting antibody drug conjugate currently in Phase 1 clinical development that combines Zanidatamab's unique design and antibody framework with Zymeworks' proprietary ZymeLink connector and cytotoxin. Zymeworks is also advancing an in-depth preclinical pipeline in oncology (including immuno-oncology drugs) and other therapeutic areas. In addition, through strategic partnerships with global biopharmaceutical companies, it is leveraging its therapeutic platform 3.
